Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Bolt Biotherapeutics, Inc. (NASDAQ:BOLTGet Free Report)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.68 and traded as low as $0.52. Bolt Biotherapeutics shares last traded at $0.53, with a volume of 318,097 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, Bolt Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $3.50.

Get Our Latest Analysis on BOLT

Bolt Biotherapeutics Stock Performance

The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average price of $0.62 and a 200 day moving average price of $0.67. The stock has a market cap of $20.20 million, a PE ratio of -0.31 and a beta of 0.93.

Bolt Biotherapeutics (NASDAQ:BOLTGet Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.02 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. Analysts expect that Bolt Biotherapeutics, Inc. will post -1.61 earnings per share for the current year.

Institutional Trading of Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. bought a new position in Bolt Biotherapeutics in the 2nd quarter worth $26,000. Acuitas Investments LLC increased its position in shares of Bolt Biotherapeutics by 21.7% during the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after buying an additional 112,555 shares during the period. Finally, FMR LLC raised its stake in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares in the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

(Get Free Report)

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.

Featured Articles

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.